Traders Market Weekly: September 3 to 9 2021

Viewing 9 posts - 31 through 39 (of 39 total)
  • Author
    Posts
  • #26997
    Truman
    Participant

    Gapping up
    In reaction to earnings/guidance:

    CURV +16.2%, LULU +13.2%, LOVE +11%, RKLB +5.7% (also awarded multi-launch deal to deploy IoT satellite constellation for Kinéis), RH +2.3%, ASX +2.3% (Aug revs) SHCR +2.3%, HQY +1.2%, JILL +1%

    Other news:

    CRDF +16% (announces Phase 1b/2 trial data showing robust objective response rate and progression free survival)
    CNTA +15.4% (reports topline data from proof-of-concept study of SerpinPC in severe hemophilia A and B patients)
    PRQR +14.5% (announces licensing and research collaboration with LLY for Axiomer RNA editing)
    SIOX +5.3% (doses first GM1 Gangliosidosis early infantile patient in ongoing Phase 1/2 study of AXO-AAV-GM1 gene therapy)
    RKLY +3.6% (expands application of non-invasive biomarker sensing technology)
    BYSI +3.4% (Three Poster Presentations About its Chemotherapy-Induced Neutropenia Prevention Program at the European Society for Medical Oncology 2021 Congress)
    CLSD +2.9% (to expand the territories covered by its exclusive license agreement with Arctic Vision)
    CHRA +2.6% (awarded 5-year fly ash sales and marketing contract for beneficial use of production fly ash at gavin power plant in Ohio)
    ZYNE +1.6% (presents data from the Phase 2 BRIGHT trial)
    NXU +1.5% (Energy Vault to accelerate global decarbonization, to list on the NYSE through merger with Novus Capital Corporation II)
    RIOT +1.2% (reports August production and operation updates)
    RYTM +1.2% (announces EAP for setmelanotide)
    TPTX +1.1% (to present abstract of early clinical data from TRIDENT-1)
    EVLO +1% (U.S. Patent and Trademark Office has issued a new composition of matter patent (No. 11,090,341) for medicines comprising pharmaceutical compositions of Veillonella parvula bacteria)

    Analyst comments:

    APP +2.8% (upgraded to Buy from Hold at Stifel)
    BMRN +1.7% (upgraded to Buy from Hold at Stifel)
    M +0.9% (upgraded to Outperform from Market Perform at Cowen)

    #26998
    Truman
    Participant

    Upgrades

    Stifel upgraded AppLovin (APP) to Buy from Hold with a price target of $90, up from $65, after taking over coverage of the name. The firm’s positive stance on the shares is based on “increased confidence” in the software platform outlook. The firm sees upside from the Adjust acquisition and a “robust” mobile games pipeline for AppLovin. Accordingly, the firm increased its adjusted EBITDA estimates to $719M and $1.04B for 2021 and 2022, respectively. The firm believes revenue synergies from the Adjust acquisition should begin to contribute more meaningfully in 2022, accelerating the “healthy” underlying trends for the software platform segment with incremental revenues flowing at very high margins.

    Canaccord upgraded Belden (BDC) to Buy from Hold with a price target of $68, up from $53. The firm believes, following its divestitures of Grass Valley and cable products, Belden, is “lighter,” with a focus on system-based solutions, which he believes the market is heavily discounting. The firm believes that only about 30% of global manufacturing capacity is using automation or smart manufacturing today and sees the need for outsourced IT/OT infrastructure growing as the complexity of networks increases, giving Belden opportunities to design, install and service these dedicated networks.

    Jefferies upgraded Banco Santander (SAN) to Hold from Underperform with a price target of EUR 3.10, up from EUR 2.60. The firm expects Santander to meet fiscal 2021 profit expectations while pending deals “should also boost” future earnings. The firm notes recent share underperformance leaves the company’s valuation less demanding.

    #26999
    Truman
    Participant

    Downgrades

    Citi downgraded Axalta Coating (AXTA) to Neutral from Buy with a price target of $32, down from $39. The firm notes higher raw material prices and low availability that persisted through summer after winter storm Uri have been exacerbated after Hurricane Ida. The firm says shortages, pricing headwinds and the effects of the semiconductor shortage on auto manufacturer builds have led him to downgrade names in the North America commodity chemicals and specialty chemicals space. The firm expects coatings companies to face another margin squeeze like they did in Q2 of this year.

    Goldman removed Devon Energy (DVN) from the firm’s Americas Conviction List and keeps a Buy rating on the shares with a $36 price target. The firm believes the shares now reflect greater recognition of Devon’s fixed and variable dividend strategy. The firmstill sees potential for dividend payout increases to drive the next leg of inflection for the shares.

    Morgan Stanley downgraded Cisco Systems (CSCO) to Equal Weight from Overweight with a price target of $59, up from $57. The firm notes Cisco’s multiple has expanded to a level nearer to its historical discount to the S&P 500 Index. While the firm remains confident in company’s growth trajectory, the firm says achieving its bull case requires a stronger software growth trajectory, putting the firm on the sidelines heading into upcoming analyst day. The firm says Cisco’s multiple re-rating is largely complete, making further appreciation dependent on earnings upside.

    #27000
    Truman
    Participant

    RBC assumed coverage of Schlumberger (SLB) with an Outperform rating and $37 price target. The firm sees Schlumberger’s scale and growing digital platform positioning it to generate improved financial returns, while the firm believes its de-carbonization services and expanding portfolio in energy transition should support future revenue growth. He thinks reducing leverage and showing solid dividend growth will “be key to generating generalist investor interest,” the analyst added.

    BMO resumed coverage of Brookfield Infrastructure Partners (BIP) with an Outperform rating with a price target of $63, up from $61. The firm notes that the company’s organic growth is expected to be near the upper end of its targeted range, and the firm sees upside to estimates as mature investments are sold and the capital is redeployed into higher-yielding opportunities. The firm adds that liquidity for Brookfield Infrastructure is at record levels and the deal pipeline is robust.

    JMP Securities initiated coverage of Goosehead Insurance (GSHD) with an Outperform rating and $170 price target. The firm notes Goosehead is a personal lines insurance agency that has a superior mousetrap versus peers that should result in much stronger growth over the long run. The firm says the personal lines insurance market is massive at roughly $350B in annual premiums and that the independent agency channel where Goosehead is focused has been steadily gaining share. The firm believes Goosehead’s value proposition to both customers and agents is better than peers.

    Barclays reinstated coverage of Humana (HUM) with an Overweight rating and $500 price target following the company’s acquisition of the remaining 60% of Kindred at Home. The firm still views the upside case on 2022 earnings as quite compelling and believes Humana continues to be well positioned for growth under a CMS-friendly Biden administration.

    #27002

    [color=purple][i][b]This may be more of the TRUE “FOLLOW THE SCIENCE”
    As I love listening to this series of Columbia MED UNIV lectures over past 2 years 8)
    And in contrast to SIX PRONG” COVID measures coming at 5 pm today 😉 :whistle: :whistle: :whistle: :whistle:[/b][/i][/color]

    #27004

    [size=5][b][color=red]Dow 34,879.38 -151.69 -0.43%
    S&P 500 4,493.28 -20.79 -0.46%
    Nasdaq 15,248.25 -38.38 -0.25%
    GlobalDow 4,042.77 -14.56 -0.36%
    Gold 1,796.30 2.80 0.16%
    Oil 67.92 -1.38 -1.99%[/color][/b][/size]

    #27005

    [color=purple][i][b]6 PRONG COVID plan – requires forced (no exception) VAX for all FED & large company employees
    Some folks who have had COVID have natural RNA antibodies
    and some have immunity restrictions + even freedom of choice legal challenges ahead
    And the true science is that VAX is helpful — but COVID mitigation is still not that simple
    #46 is doing no better than #45 in stopping this serious disease [/b][/i][/color]

    https://www.newsmax.com/us/vaccine-mandate-private-employees/2021/09/09/id/1035759/

    #27010

    [color=purple][size=5][i]Ohhhh the humanity — KING GEORGE wanted to have all tea TAXXED
    While today KING JOE wants to get us all VAXXED & TAXXED 😉 :woohoo: :woohoo: :woohoo:[/i][/size][/color]

    #27011

    [color=red][size=5][b]Dow 34,607.72 -271.66 -0.78%
    S&P 500 4,458.58 -34.70 -0.77%
    Nasdaq 15,115.49 -132.76 -0.87%
    GlobalDow 4,030.32 -12.02 -0.30%
    Gold 1,789.60 -10.40 -0.58%
    Oil 69.59 1.45 2.13%[/b][/size][/color]

    [color=purple][i][b]All time FAV & hoping theme extends into tomorrow
    Felix Cav. of Rascals/Traffic one of best keyboard//moog of all time (1971)[/b][/i][/color] 8)

Viewing 9 posts - 31 through 39 (of 39 total)
  • You must be logged in to reply to this topic.